AN2 Therapeutics growth metrics data for the quarter ended Jun 2026. These growth metrics cover 17 quarters of results from Jun 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Growth Metrics | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | |||||||||||||||||
| Return on Assets [ROA] Growth (1y)ROA Growth (1y) | -2173.00 | -3192.00 | -1774.00 | -911.00 | -310.00 | -52.00 | -1115.00 | -648.00 | 171.00 | 1,167.00 | 1,323.00 | -37.00 | 606.00 | 468.00 | |||
| Return on Assets [ROA] Growth (3y)ROA Growth (3y) | -2312.00 | -2076.00 | -1566.00 | -1596.00 | 467.00 | 1,584.00 | |||||||||||
| Return on Assets [ROA] (QoQ)ROA (QoQ) | 238.00 | -505.00 | -664.00 | -1242.00 | -781.00 | 913.00 | 199.00 | -640.00 | -523.00 | -150.00 | 665.00 | 179.00 | 473.00 | 5.00 | -694.00 | 821.00 | 336.00 |
| Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y) | -2637.00 | -3982.00 | -2295.00 | -1001.00 | -1524.00 | -1442.00 | -112.00 | ||||||||||
| Return on Capital Employed [ROCE] Growth (3y)ROCE Growth (3y) | -2556.00 | 368.00 | 1,872.00 | ||||||||||||||
| Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) | 295.00 | -578.00 | -884.00 | -1471.00 | -1049.00 | 1,109.00 | 409.00 | 491.00 | 1,453.00 | 455.00 |